Bicycle therapeutics announces presentations at the aacr annual meeting 2021

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that for the first time, preclinical work describing the discovery of bt7480, a novel nectin-4/cd137 tumor-targeted immune cell agonist (ticatm), will be presented virtually in a “new drugs on the horizon” session at the american association for can
BCYC Ratings Summary
BCYC Quant Ranking